The University of Oxford’s R21/Matrix-M vaccine is the very first malaria vaccine to achieve the 75% efficacy goal.
The World Health Organization, or WHO, has advocated for the broad deployment of a malaria vaccine that is incredibly successful.
The only additional malaria vaccine to be suggested by the WHO is the R21/Matrix-M vaccine, which was created by the School of Medicine of Oxford. It is the initial attempt to achieve the aim of 75% efficacy set by the WHO.
Half a million people every year die from malaria, a mosquito-borne illness that primarily affects young children and pregnant women.
“As a researcher on malaria, I used to daydream about the possibility of developing a malaria vaccine that is both secure and efficient. The WHO’s director general, Dr. Tedros Adhanom Ghebreyesus, stated that there are now two.
There is a significant need for immunizations. However, there are just a few RTS,S vaccines left in circulation when the WHO authorized it in 2021. The second WHO-recommended vaccine is anticipated “to protect more kids faster, and to bring us nearer to our objective of a malaria-free future,” according to Tedros.
According to the BBC, the serum laboratory of India, the largest vaccine maker in the world by dose, is already scheduled to produce more than 100 million doses year and has ambitions to increase that number to 200 million. Each medication costs from $2 and $4, and each person need four doses. That is around half of what RTS,S costs. There have only been 18m dosages of RTS,S so yet.
According to the BBC, the serum laboratory of India, the largest vaccine maker in the world by dose, is already scheduled to produce more than 100 million doses year and has ambitions to increase that number to 200 million. Each medication costs around $2 and $4, and each person need four doses. That is around half of what RTS,S costs. There have only been 18m dosages of RTS,S so yet.
The WHO’s regional coordinator for Africa, Dr. Matshidiso Moeti, stated: “This second vaccination holds real promise to close the significant demand and supply imbalance. The two vaccinations, if widely distributed and distributed at scale, could support efforts to prevent and control malaria and protect tens of thousands of children across Africa from this fatal illness.